Clinical trials: Dose Finding Study
Japanese Encephalitis Virus Disease
A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults
This is a 2-Stage, Phase I/II Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis mRNA Vaccines (GBP560) in Healthy Adults (Aged 18 Years and Older)
- Trial name
- NCT06680128
- Testing
- GBP560-A, GBP560-B, IXIARO
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
Chlamydia Trachomatis Immunization
Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years
The purpose of this study is to evaluate the safety, efficacy, and immunogenicity of different dose levels (low, medium, and high) of Chlamydia messenger ribonucleic acid (mRNA) Vaccine candidate in adult participants aged 18 to…
- Trial name
- NCT06891417
- Testing
- Chlamydia mRNA Vaccine
- Where
- 7 sites in Australia
- Volunteers
- 1,560 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy
Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain
Development of an S. sonnei human challenge model using a newly manufactured lyophilized lot of S. sonnei strain 53G (Lot 1794) that can be used in the future as a challenge strain for all S. sonnei vaccine candidates.
- Trial name
- NCT02816346
- Testing
- Shigella sonnei 53G
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- PATH
Dose Finding Study
Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Western Male Subjects, Preliminary Food Effect Analysis, and an Ethnic Comparison With Japanese Subjects
The primary purpose of this study was to evaluate the safety, tolerability, and pharmacokinetics of TAK-438 following single or multiple doses of TAK-438 in healthy Western men, to investigate the effect of food on the…
- Trial name
- NCT02141698
- Testing
- TAK-438, Esomeprazole
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy
Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066
The study is carried out in order to determine the relationship between AZD2066 exposure and mGluR5 receptor occupancy in the brain and to demonstrate that AZD2066 can displace [11C]AZ12713580 from mGluR5 binding-sites in the…
- Trial name
- PET (NCT00686504)
- Testing
- AZD2066, radioligand [11C] AZ12713580
- Where
- Sweden
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Major Depressive Disorder, Psychotic Disorders
Safety Study of ORG 34517 for Major Depression With Psychotic Features
Patients suffering from Major Depressive Disorder with Psychotic features who have received no changes in their medications in the previous two weeks will receive "usual" treatment of antidepressants, antipsychotics and/or mood…
- Trial name
- NCT00226278
- Testing
- ORG 34517
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Hypotension, Nausea
Ideal Dose of Phenylephrine to Treat Low Blood Pressure During Cesarean Section
The purpose of this study is to determine the minimum effective bolus dose of phenylephrine to prevent post-spinal hypotension in Cesarean section in 95 % of our patients.
- Trial name
- NCT00379691
- Testing
- phenylephrine
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Cytomegalovirus Infection
Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults
This clinical study will assess the safety and immunogenicity of 3 dose levels of mRNA-1647 cytomegalovirus vaccine in CMV-seronegative and CMV-seropositive healthy adults 18-40 years of age.
- Trial name
- NCT04232280
- Testing
- mRNA-1647
- Where
- 9 sites in United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Safety, Vaccine Reaction
Phase-I Study to Evaluate the Safety and Immunogenicity of a Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults
A pneumonia of unknown cause detected in Wuhan, China, was first reported in December 2019. On 08 January 2020, the pathogen causing this outbreak was identified as a novel coronavirus 2019.
- Conditions
- Safety, Vaccine Reaction, Vaccine Adverse Reaction, Immunization; Infection
- Trial name
- NCT05171946
- Testing
- S.opt.FL COVID-19 pDNA vaccine
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Iman Almansour
Sars-CoV-2 Infection
Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 Prevention
The investigated product is a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Booster Vaccine candidate optimized for the Omicron/BA.2 variant.
- Trial name
- NCT05844202
- Testing
- Alveavax-v1.2, Janssen Ad26.COV2.S
- Where
- 8 sites in South Africa
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Alvea Holdings, LLC
Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2
Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens
This dose finding, multi-cohort study is designed to evaluate the safety and efficacy of intradermally-injectedTNX-2100, synthesized SARS-CoV-2 peptide antigens and assess the presence and magnitude of DTH reactions.
- Trial name
- COVID-19 DTH (NCT05216510)
- Testing
- TNX-2110, TNX-2120, TNX-2130
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Tonix Pharmaceuticals, Inc.
Pregnancy, Nutritional Status
Antenatal Vitamin D3 Dose-finding and Safety Study
This is a preliminary study of oral vitamin D3 supplementation in pregnant and non-pregnant women of reproductive age in Bangladesh.
- Conditions
- Pregnancy, Nutritional Status, Vitamin D
- Trial name
- AViDD-1 (NCT00938600)
- Testing
- Vitamin D3
- Where
- Bangladesh
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Healthy
A Study in Healthy Men to Find Out How BI 1015550 is Taken up and Handled by the Body
The main objective of this trial is to investigate the basic pharmacokinetics of BI 1015550 and its metabolite BI 764333 (M480), [14C]-radioactivity, including mass balance, excretion pathways and metabolism following a single…
- Trial name
- NCT04771286
- Testing
- BI 1015550 (C-14)
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
The Fructose and Allulose Catalytic Effects (FACE) Trial
Diabetes remains one of the most important unmet prevention and treatment challenges, and the prevalence of diabetes continues to grow. Some functional food ingredients may hold promise as potential therapies for diabetes.
- Trial name
- NCT02459834
- Testing
- Allulose, Fructose, Control
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Tuberculosis
Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers
This is a two-part randomized, placebo-controlled, observer-blind, safety and dose-finding Phase Ib/IIa study. This study will evaluate up to four dose levels of the BNT164 investigational vaccines (BNT164a1 and BNT164b1) to…
- Trial name
- NCT05547464
- Testing
- BNT164a1, BNT164b1
- Where
- 8 sites in Mozambique, South Africa
- Volunteers
- 497 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Pharmacokinetics of Mirabegron, Bioavailability
A Study to Find Out How Much Mirabegron Gets Into the Body After Dosing With a Tablet Formulation
A study to evaluate how much of the active compound of mirabegron comes into the blood circulation when given as a controlled-release pill as compared to given intravenously.
- Conditions
- Pharmacokinetics of Mirabegron, Bioavailability, Healthy Subjects
- Trial name
- NCT01478529
- Testing
- mirabegron OCAS, mirabegron
- Where
- Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Respiratory Tract Infections
A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults
The study will describe the safety, tolerability, and immunogenicity of up to 6 RSV vaccine formulations when administered alone or concomitantly with seasonal inactivated influenza vaccine (SIIV).
- Trial name
- NCT03529773
- Testing
- Formulation A, Formulation B
- Where
- 40 sites in United States
- Volunteers
- 1,235 people, healthy volunteers welcome
- Sponsor
- Pfizer
Meningococcal Disease
Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate Vaccines
Invasive meningococcal disease is a worldwide problem with serious repercussions for those affected. Vaccination is recognized as the best way to combat it.
- Trial name
- NCT01782066
- Testing
- MEN-ACYW135 reduced-dose intradermal administration
- Where
- Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Arthroscopic Knee Surgery
Study to Find Optimal Dose of Local Spinal Anesthetic (Mepivacaine) Combined With Narcotic (Fentanyl) For Knee Surgery
Prolonged motor block and delayed ability to walk are limitations of spinal anesthesia in ambulatory (same-day) surgery. This can be improved by lowering the dose of local anesthetic (a medication that, when injected around…
- Trial name
- NCT01701102
- Testing
- Mepivacaine (24 mg) plus fentanyl, Mepivacaine (27 mg) plus fentanyl, Mepivacaine (30 mg) plus fentanyl
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Hospital for Special Surgery, New York
Tick-borne Encephalitis
Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.
The purpose of this study is to investigate the safety and immunogenicity of three different concentrations of a TBE vaccine in healthy children aged 1 to 6 years.
- Trial name
- NCT00161772
- Testing
- Tick-borne Encephalitis Vaccine
- Where
- 23 sites in Austria, Germany
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer